Larvol Delta - First-Clinical-Study-with-AP30663--a-K-2-Channel-Inhibitor-in-Development-for-Conversion-of-Atrial-Fibrillation

AP30663 - Acesion

http://www.ncbi.nlm.nih.gov/pubmed/32725783

Jul 30, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next